FDA Approves Eli Lilly's GLP-1 Pill Foundayo: Second Oral Obesity Drug Hits US Market

The FDA has approved Eli Lilly's once-daily obesity pill Foundayo, the second oral GLP-1 medication to reach the US market, marking a significant milestone in the multibillion-dollar weight loss drug race.

The Drug

• Name: Foundayo (generic: orforglipron)
• Manufacturer: Eli Lilly (also makes Zepbound/Mounjaro injections)
• Dosage: Once daily pill, no food or water restrictions
• Category: GLP-1 receptor agonist (same class as Ozempic, Wegovy)
• Mechanism: Mimics natural hormones that regulate blood sugar, slow digestion, and signal fullness

How It Compares

Clinical Results

• Highest dose: Average 27 pounds (12.4%) weight loss over 18 months
• Placebo: Average 2 pounds (<1%) over same period
• Comparison: Lilly's injectable tirzepatide (Zepbound) achieves >20% weight loss
• No head-to-head trials between Foundayo and Wegovy pill yet

Why Pills Matter

Ken Custer, EVP at Eli Lilly:

"Beyond supply and affordability, one of the bigger barriers to adoption has been that some patients just don't want to take an injection... For patients looking to get started with their weight management journey, maybe a pill is an easier place for them to start."

Pills address multiple challenges:

1. Needle phobia: Many patients avoid injectables
2. Manufacturing: Pills are easier to produce than injectables
3. Supply stability: GLP-1 drugs were in severe shortage from late 2022 through early 2025
4. Market expansion: Pills could reach patients who would never consider injections

Market Impact

The GLP-1 market is expected to exceed $100 billion by 2030. With two oral options now available:

• Competition will likely drive prices down over time
• Insurance coverage may expand as oral options reduce perceived severity
• The obesity treatment landscape is fundamentally changing